Abstract：
:Anticoagulation is often used in superior vena cava syndrome (SVCS) associated with cancer (i.e malignant SVCS), even without thrombosis, but its effect on outcomes has not been reported. We aimed to determine factors and outcomes associated with thrombosis and anticoagulation in malignant SVCS. Patients with malignant SVCS diagnosed on computerized tomography (CT) were retrospectively included, indexed at diagnosis and followed for 6 months using medical records. The cohort included 183 patients with malignant SVCS of which 153 (84%) were symptomatic. Thirty of the 127 patients (24%) with a reviewable baseline CT had thrombosis of the SVC or tributaries at diagnosis. Patients with baseline thrombosis more often had symptomatic SVCS (p < 0.01). 70% (21/30) of patients with thrombosis and 52% (49/97) of those without thrombosis at baseline received anticoagulation, most often at therapeutic doses. Thrombosis occurred in 5/39 patients with anticoagulation (13%) compared to 2/18 (11%) of those without, during follow-up (p = 0.85). Anticoagulation was associated with a reduction in risk of SVC stent placement during follow-up that did not reach statistical significance (HR 0.47, 95% CI 0.2-1.13, p = 0.09). Major bleeding occurred in 7 (4%) patients, six of whom received anticoagulation (four therapeutic and two intermediate dose). Neither thrombosis nor anticoagulation affected survival. Anticoagulation is commonly used as primary prevention but its benefit remains to be proven. The role of reduced-dose anticoagulation in non-thrombotic malignant SVCS should be prospectively assessed.
journal_name
J Thromb Thrombolysisjournal_title
Journal of thrombosis and thrombolysisauthors
Ratzon R,Tamir S,Friehmann T,Livneh N,Dudnik E,Rozental A,Hamburger-Avnery O,Pereg D,Derazne E,Brenner B,Raanani P,Ten Cate H,Spectre G,Leader Adoi
10.1007/s11239-018-1747-6subject
Has Abstractpub_date
2019-01-01 00:00:00pages
121-128issue
1eissn
0929-5305issn
1573-742Xpii
10.1007/s11239-018-1747-6journal_volume
47pub_type
杂志文章abstract：:Gastrointestinal bleeding is the most common bleeding complication during anticoagulant therapy. A reliable bleeding risk score can help the clinician assess risk of bleeding in individual patients and select the anticoagulant regimen. This study retrospectively analyzed the data of patients with atrial fibrillation w...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章
doi：10.1007/s11239-020-02152-1
更新日期：2021-01-01 00:00:00
abstract：:To analyze the efficacy and safety of activated prothrombin complex concentrates (aPCC) and four-factor prothrombin complex concentrates (4F-PCC) to prevent hematoma expansion in patients taking apixaban or rivaroxaban with intracranial hemorrhage (ICH). In this multicenter, retrospective study, sixty-seven ICH patien...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章
doi：10.1007/s11239-020-02154-z
更新日期：2021-01-01 00:00:00
abstract：:Coagulation dysfunction and inflammatory status were compared between diabetic and non-diabetic COVID-19 patients. The standardized mean difference (SMD) and its 95% confidence interval (CI) was computed for the difference of inflammatory and hypercoagulability markers. The levels of serum ferritin (standardized mean ...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 信件
doi：10.1007/s11239-020-02270-w
更新日期：2020-09-05 00:00:00
abstract：:Venous thromboembolism (VTE) is a common complication of hematologic malignancies. Prolonged periods of thrombocytopenia are experienced universally by patients undergoing treatment for these diseases, yet data to guide management of anticoagulation in this setting are lacking. To obtain data on the management and out...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章
doi：10.1007/s11239-017-1539-4
更新日期：2017-11-01 00:00:00
abstract：:Stroke and venous thromboembolism (VTE) are serious and preventable thrombotic events in patients with atrial fibrillation (AF) and who undergo surgery or hospitalization, respectively. Nevertheless, thromboprophylaxis remains greatly underused. The National Quality Forum, the Agency for Healthcare Research and Qualit...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章,评审
doi：10.1007/s11239-013-0874-3
更新日期：2014-01-01 00:00:00
abstract：:Thromboembolic events are frequent and serious complications of acute lymphoblastic leukaemia treatment. The importance of chemotherapy in the pathogenesis of this increased risk is enhanced by the fact that thrombosis rarely occurs at diagnosis. Our study aims at investigating the effect of chemotherapy on pro-coagul...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章
doi：10.1007/s11239-019-01894-x
更新日期：2019-08-01 00:00:00
abstract：:The concept of a pulmonary embolism response team (PERT) is multidisciplinary, with the hope that it may positively impact patient care, hospital efficiency, and outcomes in the treatment of patients with intermediate and high risk pulmonary embolism (PE). Clinical characteristics of a baseline population of patients ...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章
doi：10.1007/s11239-019-01875-0
更新日期：2019-08-01 00:00:00
abstract：:Recent gene knockout studies on mice have shown the role of toll-like receptor 9 (TLR9) in resolution of venous thromboembolism (VTE) through sterile inflammation. However, the role of a putative functional TLR9 polymorphism (rs5743836) in risk assessment of VTE recurrence remains unknown. The aim of our study was to ...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 临床试验,杂志文章,多中心研究
doi：10.1007/s11239-017-1491-3
更新日期：2017-07-01 00:00:00
abstract：:Associations of Raynaud's phenomenon (RP) with venous thromboembolism (VTE) are unclear. We investigated the occurrence of RP together with prothrombotic state markers and fibrin clot properties in VTE patients. In this prospective cohort study we enrolled 360 patients free of known autoimmune disease. D-dimer, von Wi...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章
doi：10.1007/s11239-019-01805-0
更新日期：2019-02-01 00:00:00
abstract：:The use of magnesium therapy for acute myocardial infarction remains controversial despite recent clinical trials such as ISIS-4. Magnesium has numerous beneficial effects in the setting of myocardial infarction, including inhibitory effects on platelet aggregation. Clinical trials of magnesium therapy for myocardial ...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章
doi：10.1007/BF01064375
更新日期：1995-01-01 00:00:00
abstract：PURPOSE:To describe and compare warfarin therapy use and outcomes between warfarin-receiving patients in hospice or palliative care (HPC) and not in HPC. METHODS:This retrospective, matched analysis examined warfarin-receiving patients who did (study cohort) and did not receive (control cohort) HPC services between 20...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章
doi：10.1007/s11239-008-0210-5
更新日期：2009-04-01 00:00:00
abstract：:The goal of platelet function testing in the catheterization laboratory is to provide information about the platelet contributions to the risk of thrombotic or hemorrhagic events and optimization of anti-platelet therapy for percutaneous interventions. We present several illustrative cases in which platelet monitoring...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章
doi：10.1023/a:1011228817265
更新日期：2001-04-01 00:00:00
abstract：:The optimal antithrombotic therapy for patients undergoing TAVI with concomitant indication for oral anticoagulation remains unclear. In this high-risk population group, there is a paucity of data with regards to the use of DOACs. In the present study we compared long-term clinical outcomes of TAVI patients requiring ...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章
doi：10.1007/s11239-019-01968-w
更新日期：2020-07-01 00:00:00
abstract：:In patients with active cancer and acute venous thromboembolism (VTE), the low-molecular-weight-heparin (LMWH) dalteparin is more effective than vitamin K antagonist (VKA) in reducing the risk of recurrent venous thromboembolism (rVTE) without increasing the risk of bleeding. However, the relative benefit of LMWH vers...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 临床试验,杂志文章,多中心研究
doi：10.1007/s11239-019-01833-w
更新日期：2019-05-01 00:00:00
abstract：:In situ formation of thrombi within the cardiac cavities carries a substantial risk of morbidity and mortality due to the inherent danger of embolization to vital organs. This typically occurs in patients with underlying cardiac disorders associated with low flow state favoring regional stagnation of blood and subsequ...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章,评审
doi：10.1007/s11239-004-0210-z
更新日期：2004-10-01 00:00:00
abstract：:Early rapid platelet inhibition with abciximab before primary percutaneous coronary intervention (PPCI) for ST-segment elevation myocardial infarction (STEMI) is suggested as beneficial. In previous studies on early abciximab administration clopidogrel was administered in cathlab in low loading dose. We investigated t...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章,多中心研究,随机对照试验
doi：10.1007/s11239-010-0461-9
更新日期：2010-10-01 00:00:00
abstract：:The current, global situation regarding the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic and its potentially devastating clinical manifestations, i.e. coronavirus disease 2019 (COVID-19), took the world by storm, as millions of people have been infected worldwide and more than 1,600,000 patien...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章,评审
doi：10.1007/s11239-020-02374-3
更新日期：2021-01-15 00:00:00
abstract：:Prasugrel has been shown to be superior to clopidogrel in the setting of ACS patients undergoing coronary angioplasty. However, few data have been reported so far on those patients who switch from clopidogrel to prasugrel after coronary angioplasty. Aim of the current study was to evaluate the safety of prasugrel load...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 临床试验,杂志文章
doi：10.1007/s11239-013-1039-0
更新日期：2014-10-01 00:00:00
abstract：:Anticoagulant plasma concentrations and patient characteristics might affect the benefit-risk balance of therapy. The study objective was to assess the impact of model-predicted rivaroxaban exposure and patient characteristics on outcomes in patients receiving rivaroxaban for venous thromboembolism (VTE) prophylaxis (...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章
doi：10.1007/s11239-020-02078-8
更新日期：2020-07-01 00:00:00
abstract：:The direct oral anticoagulant dabigatran does not require therapeutic drug monitoring, however emergency measurements are gaining importance. Current assays feature good performance at intermediate and high dabigatran concentrations but show limited accuracy at low concentrations. This area requires more attention as ...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 临床试验,杂志文章
doi：10.1007/s11239-019-01981-z
更新日期：2020-04-01 00:00:00
abstract：:Infarct artery stenting with adjunctive abciximab therapy is widely used treatment for patients with acute myocardial infarction (AMI). However, bleeding complications have been associated with a worse clinical outcome. Randomized trials in elective patients have shown that postprocedural protamine administration is s...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章
doi：10.1007/s11239-010-0481-5
更新日期：2010-11-01 00:00:00
abstract：:Postmortem studies reported plaque erosion is frequent in young women. Recent in vivo studies failed to show age and sex differences in the plaque erosion prevalence. The aim of this study was to investigate the prevalence of plaque erosion by age and sex among acute coronary syndromes (ACS) patients. From 1699 ACS pa...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 临床试验,杂志文章,多中心研究
doi：10.1007/s11239-019-01969-9
更新日期：2020-04-01 00:00:00
abstract：:Pylephlebitis, or suppurative thrombophlebitis of the portal vein, typically occurs in the context of an intraabdominal infection or abdominal sepsis. Antibiotics are the mainstay of treatment. The role of anticoagulation in the management of pylephlebitis is controversial, and data regarding its impact on outcomes is...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章
doi：10.1007/s11239-019-01949-z
更新日期：2020-02-01 00:00:00
abstract：:Pulmonary embolism (PE) is a leading cause of cardiovascular mortality. We intended to evaluate the awareness and management status of PE among Chinese physicians and provide the basis for establishing Chinese clinical guidelines on PE. We designed a nationwide survey to collect data on physicians' awareness of diagno...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章
doi：10.1007/s11239-018-1788-x
更新日期：2019-04-01 00:00:00
abstract：:Patients with heparin-induced thrombocytopenia (HIT) type II require anticoagulation with non-heparin immediate acting anticoagulants. Danaparoid may cross react with HIT-antibodies and lepirudin may generate anti-lepirudin antibodies influencing anticoagulation. We hypothesised, that the synthetic small molecular thr...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章
doi：10.1007/s11239-005-0942-4
更新日期：2005-02-01 00:00:00
abstract：:Measurements of infarct size by use of tripenyltetrazoliumchloride (TTC) is a widely accepted method used to delineate the extent of myocardial necrosis following coronary occlusion and reperfusion in various animal experiments. There is controversy, however, regarding the optimal reperfusion time for estimating the m...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章
doi：10.1023/a:1018770711705
更新日期：2000-10-01 00:00:00
abstract：:The recent development and approval of novel oral anticoagulants represents a significant success in the intelligent design of target-specific therapeutics. However, while these agents obviate many of the shortcomings of their predecessor (warfarin), they present novel challenges in pharmacologic management as well. E...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章,评审
doi：10.1007/s11239-013-0991-z
更新日期：2014-01-01 00:00:00
abstract：:A significant proportion of the outcomes reported in trials assessing venous thromboembolism (VTE) prophylaxis in medical patients are related to asymptomatic events found on routine imaging studies. The implications of these events are controversial. Moreover, such trials did not always reflect the patient mix in tod...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章,评审
doi：10.1007/s11239-012-0730-x
更新日期：2012-07-01 00:00:00
abstract：:High central aortic pulse pressure (CPP) and thrombin-induced platelet-fibrin clot strength (TIP-FCS) have been associated with ischemic outcomes in patients with coronary artery disease in separate studies. But, the ischemic risk associated with these factors has never been analyzed in a single study and their interr...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章
doi：10.1007/s11239-017-1524-y
更新日期：2017-08-01 00:00:00
abstract：:Differences in genetic makeup or polymorphisms can affect individual drug response. Detecting genetic variation may help predict how a patient will respond to a drug and could be used as a tool to select optimal therapy, tailor dosage regimens, and improve clinical outcomes. The data are replete relative to the therap...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章,评审
doi：10.1023/a:1022066305399
更新日期：2002-08-01 00:00:00
